Comorbidities Articles

Discover more about the comorbidities of NASH / NAFLD through articles on NASH commentary content ▶ from a study obtained from expert doctors worldwide.

Sugar and fat increase the risk of advanced liver disease

In this editorial, P. Manka Essen University Hospital, Germany) and W. K. Syn (Medical University of South Carolina, USA) comment a study by Benhammou and colleagues, who evaluated the effects of NAFLD risk factors including obesity and diabetes on the long-term outcomes of patients with HCV treated with direct-acting antivirals...

Read MoreSugar and fat increase the risk of advanced liver disease

NAFLD patients and PCI: In-hospital outcomes

This study by H. Ali et al. (Rutgers University New Jersey Medical School, USA) aims to explore outcomes in 429,855 patients who underwent percutaneous coronary intervention with or without placement of drug-eluting stents to determine whether the concurrent diagnosis of NAFLD led to worse in-hospital outcomes...
Read MoreNAFLD patients and PCI: In-hospital outcomes

NAFLD prevalence in Type 1 diabetes patients

The authors reviewed and screened references in order to estimate NAFLD prevalence in patients with type 1 diabetes, and to explore associated characteristics and outcomes. According to this review, NAFLD prevalence in patients with type 1 diabetes is considerable and is highly dependent on the specific diagnostic modality...
Read MoreNAFLD prevalence in Type 1 diabetes patients

Fatty liver index and risk of hypertension

Little data are showing the association between NAFLD and hypertension in a large-scale cohort study. J. H. Roth et al. (Chungnam National University School of Medicine, Daejeon, Korea) evaluated the ability of the fatty liver index to predict the development of hypertension in healthy individuals, in a large cohort of 334,280 healthy individuals...
Read MoreFatty liver index and risk of hypertension

Review: NAFLD, driver of chronic kidney disease

The relationship between NAFLD and chronic kidney disease has attracted much attention recently. NAFLD and chronic kidney disease may share common pathogenic mechanisms, such as insulin resistance, type 2 diabetes mellitus, hyperlipidemia and obesity, and thus may potentially share same therapeutic targets. Growing evidence suggests...
Read MoreReview: NAFLD, driver of chronic kidney disease

Treatment of 3 major risk factors and fibrosis stage regression

Currently, no established hierarchy exists for the influence of metabolic risk factors on NAFLD progression. In this retrospective cohort study, V. J. H Yao et al. (CUNY School of Medicine/Sophie Davis Biomedical Education Program, New York, USA) investigated and ranked the independent and combined effects of three major risk...
Read MoreTreatment of 3 major risk factors and fibrosis stage regression

NAFLD: an increased risk of severe of COVID-19

This meta-analysis aimed to evaluate if MAFLD is associated with a more severe disease course of COVID-19. P. J. Hegyi et al. (Medical School, University, Pécs, Hungary) included nine studies in this quantitative and qualitative synthesis. MAFLD and NAFLD are associated with a more severe clinical picture of COVID-19. These results support...
Read MoreNAFLD: an increased risk of severe of COVID-19

CNS dysfunctions as extrahepatic manifestations of NAFLD/NASH

Increasing evidences suggest that a correlation exists between NAFLD/NASH and central nervous system diseases or dysfunctions such as depression, mild cognitive impairment, Alzheimer’s disease, and dementia. In this review, M. Colognesi et al. (University of Padova, Italy) summarise the main correlations...
Read MoreCNS dysfunctions as extrahepatic manifestations of NAFLD/NASH

European NAFLD guidelines: limitations when applied to T2D patients

G. Besutti et al. aimed to evaluate the feasibility and efficiency of a guidelines-compliant NAFLD assessment algorithm in patients with newly diagnosed type 2 diabetes. Consecutive patients newly diagnosed with T2D without coexisting liver disease or excessive alcohol consumption were enrolled. They were stratified...
Read MoreEuropean NAFLD guidelines: limitations when applied to T2D patients